Within just one day, Robert Duggan, co-CEO and chairman of Summit Therapeutics, watched his net worth more than double. This seemed to be because a drug candidate for lung cancer performed incredibly well. One of the companies that he leads, Summit Therapeutics, experienced a 272% rise in its stock price. It was after this clinical trial of their candidate drug ivonescimab had a positive result for them in phase 3.
(Image not shown due to low ratings)
Images were hidden due to low ratings.